Consolidation PD-(L)1 inhibition following concurrent chemoradiation for unresectable stage III NSCLC improves survival

By | August 9, 2022
Following concurrent chemoradiation for unresectable stage III non-small cell lung cancer, both nivolumab alone and nivolumab and ipilimumab combined demonstrated improved 18- month progression-free survival compared with historical controls despite a shortened interval (6 months) of treatment.